JPS4935635B1
(en)
|
1970-12-28 |
1974-09-25 |
|
|
CH563405A5
(en)
|
1971-09-10 |
1975-06-30 |
Duschinsky Robert Dr Schweiz I |
|
DE2226295A1
(en)
|
1972-05-30 |
1973-12-20 |
Henning Berlin Gmbh |
NITRIC ACID ESTERS OF PURIN NUCLEOSIDES AND METHOD FOR MANUFACTURING THE SAME
|
DE2342479A1
(en)
|
1973-08-23 |
1975-03-13 |
Merck Patent Gmbh |
Ribonucleoside 5'-nitrates - prepd. by O-nitration of 2',3'-di-O-acyl-ribonucleosides or ribonucleoside 2',3'-ketals
|
GB2001976B
(en)
|
1977-08-03 |
1982-03-10 |
Yamasa Shoyu Kk |
S-adenosyl-l-methionine compositions and production thereof
|
US4849311A
(en)
|
1986-09-24 |
1989-07-18 |
Toa Nenryo Kogyo Kabushiki Kaisha |
Immobilized electrolyte membrane
|
US4968697A
(en)
|
1987-02-04 |
1990-11-06 |
Ciba-Geigy Corporation |
2-substituted adenosine 5'-carboxamides as antihypertensive agents
|
US5219840A
(en)
|
1987-04-06 |
1993-06-15 |
Sandoz Ltd. |
Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
|
US5221763A
(en)
*
|
1987-04-30 |
1993-06-22 |
R-Tech Ueno, Ltd. |
Prostaglandins of the F series
|
US5591887A
(en)
*
|
1987-04-30 |
1997-01-07 |
R-Tech Ueno, Ltd. |
Prostaglandins of the F series
|
US5296504A
(en)
*
|
1988-09-06 |
1994-03-22 |
Kabi Pharmacia |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
WO1990002553A1
(en)
*
|
1988-09-06 |
1990-03-22 |
Pharmacia Ab |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US6187813B1
(en)
*
|
1990-04-10 |
2001-02-13 |
Pharmacia & Upjohn Aktiebolag |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5140015A
(en)
|
1990-02-20 |
1992-08-18 |
Whitby Research, Inc. |
2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
|
US5280015A
(en)
|
1990-09-05 |
1994-01-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
|
JP3020580B2
(en)
|
1990-09-28 |
2000-03-15 |
株式会社日立製作所 |
Microwave plasma processing equipment
|
US5206222A
(en)
|
1991-05-22 |
1993-04-27 |
Vanderbilt University |
Methods for the reduction of myocardial reperfusion injury
|
HU212570B
(en)
*
|
1991-06-24 |
1996-08-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
|
US5407793A
(en)
|
1991-10-18 |
1995-04-18 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
An aqueous heart preservation and cardioplegia solution
|
US5278150A
(en)
|
1992-04-24 |
1994-01-11 |
Whitby Research, Inc. |
2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
|
DK62692D0
(en)
|
1992-05-14 |
1992-05-14 |
Novo Nordisk As |
|
AU4772493A
(en)
|
1992-07-15 |
1994-02-14 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Sulfo-derivatives of adenosine
|
US5972991A
(en)
*
|
1992-09-21 |
1999-10-26 |
Allergan |
Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5338430A
(en)
|
1992-12-23 |
1994-08-16 |
Minnesota Mining And Manufacturing Company |
Nanostructured electrode membranes
|
US5443836A
(en)
|
1993-03-15 |
1995-08-22 |
Gensia, Inc. |
Methods for protecting tissues and organs from ischemic damage
|
AU7331094A
(en)
|
1993-07-13 |
1995-02-13 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The |
A3 adenosine receptor agonists
|
US5589467A
(en)
|
1993-09-17 |
1996-12-31 |
Novo Nordisk A/S |
2,5',N6-trisubstituted adenosine derivatives
|
WO1995011681A1
(en)
|
1993-10-29 |
1995-05-04 |
Merck & Co., Inc. |
Human adenosine receptor antagonists
|
US5620676A
(en)
|
1994-03-08 |
1997-04-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biologically active ATP analogs
|
EP0704215A3
(en)
|
1994-06-02 |
1998-04-01 |
Takeda Chemical Industries, Ltd. |
Inhibitor of vascular permeability enhancer
|
GB9414193D0
(en)
|
1994-07-14 |
1994-08-31 |
Glaxo Group Ltd |
Compounds
|
US5801159A
(en)
|
1996-02-23 |
1998-09-01 |
Galileo Laboratories, Inc. |
Method and composition for inhibiting cellular irreversible changes due to stress
|
CN1164122A
(en)
|
1996-03-01 |
1997-11-05 |
株式会社日立制作所 |
Plasma processor and its treating method
|
AU2022497A
(en)
|
1996-03-13 |
1997-10-01 |
Novo Nordisk A/S |
A method of treating disorders related to cytokines in mammals
|
WO1997033879A1
(en)
|
1996-03-15 |
1997-09-18 |
Merck & Co., Inc. |
Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
EP0991414A4
(en)
|
1997-05-09 |
2002-10-02 |
Univ Pennsylvania |
Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
|
EP1037621A4
(en)
|
1997-10-15 |
2004-01-21 |
Univ Jefferson |
Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
|
US6329349B1
(en)
|
1997-10-23 |
2001-12-11 |
Trustees Of The University Of Pennsylvania |
Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
|
GB9723590D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
GB9723566D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
FR2775901B1
(en)
*
|
1998-03-13 |
2000-07-21 |
Logeais Labor Jacques |
SALTS OF CETOACIDS AND AMINO DERIVATIVES, AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS
|
GB9813535D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
CA2337499A1
(en)
|
1998-07-16 |
2000-01-27 |
The Trustees Of The University Of Pennsylvania |
Methods for reducing intraocular pressure using a3-adenosine antagonists
|
CA2347512C
(en)
|
1998-10-16 |
2005-12-06 |
Pfizer Inc. |
Adenine derivatives
|
IL127947A0
(en)
|
1999-01-07 |
1999-11-30 |
Can Fite Technologies Ltd |
Pharmaceutical use of adenosine agonists
|
US6232297B1
(en)
|
1999-02-01 |
2001-05-15 |
University Of Virginia Patent Foundation |
Methods and compositions for treating inflammatory response
|
US6403567B1
(en)
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
US6214807B1
(en)
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
DE60006116T2
(en)
|
1999-06-22 |
2004-07-08 |
CV Therapeutics, Inc., Palo Alto |
A2A RECEPTOR AGONISTS
|
US6180615B1
(en)
|
1999-06-22 |
2001-01-30 |
Cv Therapeutics, Inc. |
Propargyl phenyl ether A2A receptor agonists
|
IL133680A0
(en)
|
1999-09-10 |
2001-04-30 |
Can Fite Technologies Ltd |
Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
US6368573B1
(en)
|
1999-11-15 |
2002-04-09 |
King Pharmaceuticals Research And Development, Inc. |
Diagnostic uses of 2-substituted adenosine carboxamides
|
US6258793B1
(en)
|
1999-12-03 |
2001-07-10 |
Cv Therapeutics, Inc. |
N6 heterocyclic 5′ modified adenosine derivatives
|
GB9930071D0
(en)
|
1999-12-20 |
2000-02-09 |
Glaxo Group Ltd |
Medicaments
|
GB0003960D0
(en)
|
2000-02-18 |
2000-04-12 |
Pfizer Ltd |
Purine derivatives
|
US20010051612A1
(en)
|
2000-02-23 |
2001-12-13 |
Gloria Cristalli |
2-Thioether A2A receptor agonists
|
US20030010454A1
(en)
|
2000-03-27 |
2003-01-16 |
Bailey Andrew D. |
Method and apparatus for varying a magnetic field to control a volume of a plasma
|
US6534651B2
(en)
|
2000-04-06 |
2003-03-18 |
Inotek Pharmaceuticals Corp. |
7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
AU2001280984A1
(en)
|
2000-07-28 |
2002-02-13 |
Inspire Pharmaceuticals, Inc. |
Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
|
ATE292973T1
(en)
|
2001-01-16 |
2005-04-15 |
Can Fite Biopharma Ltd |
USE OF AN ADENOSINE A3 RECEPTOR AGONIST TO INHIBIT VIRUS REPLICATION
|
GB2372742A
(en)
|
2001-03-03 |
2002-09-04 |
Univ Leiden |
C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
|
EP1241176A1
(en)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Purine derivatives for the treatment of ischemia
|
US20040204481A1
(en)
|
2001-04-12 |
2004-10-14 |
Pnina Fishman |
Activation of natural killer cells by adenosine A3 receptor agonists
|
US20030013675A1
(en)
|
2001-05-25 |
2003-01-16 |
Boehringer Ingelheim Pharma Kg |
Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
|
US7713946B2
(en)
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
JP2004537401A
(en)
|
2001-08-08 |
2004-12-16 |
ブラウン ユニバーシティ リサーチ ファウンデーション |
Fine grinding method of hydrophobic drug
|
JP4514452B2
(en)
|
2001-10-01 |
2010-07-28 |
ユニバーシティ オブ バージニア パテント ファウンデーション |
2-propyladenosine analogs having A2A agonist activity and compositions thereof
|
ES2318129T3
(en)
|
2002-04-18 |
2009-05-01 |
Cv Therapeutics, Inc. |
PROCESS OF ARRITMIAS TREATMENT WHICH UNDERSTANDS THE ADMINISTRATION OF AN ADENOSINE A1 AGONIST WITH A BETABLOCKER.
|
EP2221054A1
(en)
|
2002-04-30 |
2010-08-25 |
Alcon, Inc. |
CDK inhibitors for lowering intraocular pressure
|
GB0216416D0
(en)
|
2002-07-15 |
2002-08-21 |
Novartis Ag |
Organic compounds
|
GB2436255B
(en)
|
2002-12-23 |
2007-11-28 |
Global Cardiac Solutions Pty L |
Organ preconditioning, arrest, protection, preservation and recovery
|
WO2004056181A1
(en)
|
2002-12-23 |
2004-07-08 |
Global Cardiac Solutions Pty Ltd |
Organ preconditioning, arrest, protection, preservation and recovery (2)
|
US8008338B2
(en)
|
2003-06-03 |
2011-08-30 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
AU2005207037A1
(en)
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
CN101010085B
(en)
|
2004-05-26 |
2012-12-26 |
伊诺泰克制药公司 |
Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
|
DE602005020286D1
(en)
|
2004-05-26 |
2010-05-12 |
Inotek Pharmaceuticals Corp |
PURE DERIVATIVES THAN ADENOSINE A 1 RECEPTOR AGONISTS AND METHOD FOR THE APPLICATION THEREOF
|
EP1768991A1
(en)
|
2004-07-12 |
2007-04-04 |
Cv Therapeutics, Inc. |
Process for the preparation of a1-adenosine receptor agonists
|
JP5688199B2
(en)
*
|
2004-10-18 |
2015-03-25 |
ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング |
Liposome composition containing an active ingredient that relaxes smooth muscle, method for producing the composition, and use as therapeutic agent
|
WO2007002139A2
(en)
|
2005-06-22 |
2007-01-04 |
The Trustees Of The University Of Pennsylvania |
Neuroprotection of retinal ganglion cells
|
WO2007064795A2
(en)
*
|
2005-11-30 |
2007-06-07 |
Inotek Pharmaceuticals Corporation |
Purine derivatives and methods of use thereof
|
EP2407171A3
(en)
|
2006-02-02 |
2012-04-11 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
CA2643503A1
(en)
|
2006-03-23 |
2007-10-04 |
Inotek Pharmaceuticals Corporation |
Purine compounds and methods of use thereof
|
US8163737B2
(en)
|
2006-06-13 |
2012-04-24 |
Vertex Pharmaceuticals Incorporated |
CGRP receptor antagonists
|
AR062046A1
(en)
|
2006-07-25 |
2008-08-10 |
Osmotica Pharmaceutical Argentina S A |
OPHTHALMIC SOLUTIONS
|
AU2007307157A1
(en)
|
2006-10-06 |
2008-04-17 |
The Trustees Of The University Of Pennsylvania |
Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure
|
SI2083629T2
(en)
|
2006-11-10 |
2015-03-31 |
Basf Se |
Crystalline modification of fipronil
|
JP5576659B2
(en)
|
2006-12-05 |
2014-08-20 |
ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング/ マギル ユニバーシティ |
Methods of using TRK receptor modulators
|
JP2008266143A
(en)
|
2007-04-16 |
2008-11-06 |
Santen Pharmaceut Co Ltd |
Glaucoma remedy containing adenosine derivative as active ingredient
|
CN101980603A
(en)
|
2007-10-11 |
2011-02-23 |
比奥根艾迪克Ma公司 |
Use of LINGO-1 and TrkB antagonists
|
US20100272711A1
(en)
|
2007-12-12 |
2010-10-28 |
Thomas Jefferson University |
Compositions and methods for the treatment and prevention of cardiovascular diseases
|
CN101983062A
(en)
|
2008-02-07 |
2011-03-02 |
吉利德帕洛阿尔托股份有限公司 |
Abca-1 elevating compounds and the use thereof
|
JP6018753B2
(en)
|
2008-11-13 |
2016-11-02 |
ザ・ジェネラル・ホスピタル・コーポレイションThe General Hospital Corporation |
Methods and compositions for controlling iron homeostasis by modulation of BMP-6
|
CA2762064A1
(en)
*
|
2009-05-01 |
2010-11-04 |
Inotek Pharmaceuticals Corporation |
Method of reducing intraocular pressure in humans
|
AU2010313544A1
(en)
|
2009-10-26 |
2012-05-10 |
Inotek Pharmaceuticals Corporation |
Ophthalmic formulation and method of manufacture thereof
|
WO2011077435A1
(en)
|
2009-12-22 |
2011-06-30 |
Bar-Ilan University |
Compositions and methods for reducing intraocular pressure
|
JP2013516495A
(en)
|
2010-01-11 |
2013-05-13 |
イノテック ファーマシューティカルズ コーポレイション |
Combinations, kits, and methods for reducing intraocular pressure
|
US20110217262A1
(en)
|
2010-03-05 |
2011-09-08 |
Kornfield Julia A |
Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
|
ES2613255T3
(en)
*
|
2010-03-19 |
2017-05-23 |
Inotek Pharmaceuticals Corporation |
Combined compositions of A1 adenosine agonists and non-selective β-adrenergic receptor blockers to reduce intraocular pressure
|
PL2555775T3
(en)
|
2010-03-19 |
2017-08-31 |
Inotek Pharmaceuticals Corporation |
Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure
|
BR112012023747A2
(en)
|
2010-03-26 |
2016-08-23 |
Inotek Pharmaceuticals Corp |
adenosine compounds and their use
|
JP2013523739A
(en)
*
|
2010-03-26 |
2013-06-17 |
イノテック ファーマシューティカルズ コーポレイション |
Method for reducing intraocular pressure in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
|